ARTV Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: Benzinga - Mentions: PBM PACS ZYXI BRTX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

2 months ago - By: Benzinga

Why Is Artiva Up Today?

4 months ago - By: The Motley Fool

Artiva (ARTV) Q2 Loss Widens 19.7%

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

2 months ago - By: Stocktwits - Mentions: IBBQ BIB TSLA

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

2 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

2 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

4 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

4 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

4 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

7 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

7 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

7 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

7 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

7 months ago - By: Artiva Biotherapeutics, Inc.

ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock News

ARTV Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Why Is Artiva Up Today?

Artiva (ARTV) Q2 Loss Widens 19.7%

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights